Celgene Gets Antitrust Green Light For $7.2B Receptos Deal
Celgene Corp. said Tuesday that it has received tacit antitrust clearance for its $7.2 billion expansion of its inflammation and immunology portfolio through the acquisition of Receptos Inc., after the Hart-Scott-Rodino...To view the full article, register now.
Already a subscriber? Click here to view full article